Endonovo Therapeutics, Inc. announced a new non-exclusive stocking distributor agreement with Pulse Therapeutics Technology, Inc. to purchase and distribute its SofPulse® medical devices into Mexico and Costa Rica. The Distributor, recognizing the treatment potential of the SofPulse® PEMF (Pulsed Electro Magnetic Frequency) device, recently purchased in excess of $100,000 of product for testing and marketing in Mexico and Costa Rica, and the test was successful, and the stocking Distributor has placed an initial order of $300,000. Endonovo – through its subsidiary SofPulse, Inc. – will work closely with the Distributor to provide ongoing support and training to ensure successful implementation of the SofPulse® in clinics and hospitals in the region.

The Company will establish a dedicated customer service team to support its continued international expansion. The Company's “Go-to-Market” strategy for SofPulse® is continuing to move forward aggressively. The Company is presently negotiating to expand distribution of SofPulse® through additional major distribution partners in South and Central America.

It is concurrently continuing licensing and distribution contract discussions with recognized distribution partners in Australia, Europe and various Southeast Asian markets. Additionally, the SofPulse® device is expected to obtain Taiwan FDA clearance later in 2023 to sell and distribute throughout Taiwan through a previously announced partnership with Evermed Medical Enterprise Ltd.